Generic drug: osimertinib
Brand name: Tagrisso
What is Tagrisso (osimertinib), and how does it work?
Tagrisso (osimertinib) is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s):
- to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery, or
- as your first treatment when your lung cancer has spread to other parts of the body (metastatic), or
- when your lung cancer has spread to other parts of the body (metastatic) and you have had previous treatment with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working.
Your healthcare provider will perform a test to make sure that Tagrisso is right for you.
It is not known if Tagrisso is safe and effective in children.
What are the side effects of Tagrisso?
Tagrisso may cause serious side effects, including:
- lung problems. Tagrisso may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever.
- heart problems, including heart failure. Tagrisso may cause heart problems that may lead to death. Your healthcare provider should check your heart function before you start taking Tagrisso and during treatment as needed.
- severe blistering or peeling of skin. Seek medical attention right away if you develop these symptoms.
- target lesions, which are skin reactions that look like rings. Seek medical attention right away if you develop these symptoms.
The most common side effects of Tagrisso are:
- low white blood cell counts
- low platelet counts
- muscle, bone, or joint pain
- changes in your nails, including: redness, tenderness, pain, inflammation, brittleness,
- dry skin
- mouth sores
- low red blood cell counts (anemia)
- rash separation from the nailbed, and shedding of nail
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Tagrisso. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800FDA-1088.
What is the dosage for Tagrisso?
First-line Treatment Of EGFR Mutation-Positive Metastatic NSCLC
- Tagrisso is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
- Tagrisso is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
- Select patients with resectable tumors for the adjuvant treatment of NSCLC with Tagrisso based on the presence of EGFR exon 19 deletions or exon 21 L858R mutations in tumor specimens.
- Select patients for the first-line treatment of metastatic EGFR-positive NSCLC with Tagrisso based on the presence of EGFR exon 19 deletions or exon 21 L858R mutations in tumor or plasma specimens. If these mutations are not detected in a plasma specimen, test tumor tissue if feasible.
- Select patients for the treatment of metastatic EGFR T790M mutation-positive NSCLC with Tagrisso following progression on or after EGFR TKI therapy based on the presence of an EGFR T790M mutation in tumor or plasma specimens.
- Testing for the presence of the T790M mutation in plasma specimens is recommended only in patients for whom a tumor biopsy cannot be obtained. If this mutation is not detected in a plasma specimen, re-evaluate the feasibility of biopsy for tumor tissue testing.
- Information on FDA-approved tests for the detection of EGFR mutations is available at http://www.fda.gov/companiondiagnostics.
- The recommended dosage of Tagrisso is 80 mg tablet once a day. Tagrisso can be taken with or without food.
- If a dose of Tagrisso is missed, do not make up the missed dose and take the next dose as scheduled.
- Treat patients in the adjuvant setting until disease recurrence, or unacceptable toxicity, or for up to 3 years.
- Treat patients with metastatic lung cancer until disease progression or unacceptable toxicity.
- Disperse tablet in 60 mL (2 ounces) of non-carbonated water only.
- Stir until tablet is dispersed into small pieces (the tablet will not completely dissolve) and swallow immediately.
- Do not crush, heat, or ultrasonicate during preparation. Rinse the container with 120 mL to 240 mL (4 to 8 ounces) of water and immediately drink.
- If administration via nasogastric tube is required, disperse the tablet as above in 15 mL of non-carbonated water, and then use an additional 15 mL of water to transfer any residues to the syringe.
- The resulting 30 mL liquid should be administered as per the nasogastric tube instructions with appropriate water flushes (approximately 30 mL).
- If concurrent use is unavoidable, increase Tagrisso dosage to 160 mg daily when co-administering with a strong CYP3A inducer. Resume Tagrisso at 80 mg 3 weeks after discontinuation of the strong CYP3A4 inducer.
Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC
Recommended Dosage Regimen
Administration To Patients Who Have Difficulty Swallowing Solids
Table 1: Recommended Dosage Modifications for Tagrisso
|Target Organ||Adverse Reaction*||Dosage Modification|
|Pulmonary||Interstitial lung disease (ILD)/Pneumonitis s||Permanently discontinue Tagrisso.|
|Cardiac||QTc† interval greater than 500 msec on at least 2 separate ECGs‡||Withhold Tagrisso until QTc interval is less than 481 msec or recovery to baseline if baseline QTc is greater than or equal to 481 msec, then resume at 40 mg dose.|
|QTc interval prolongation with signs/symptoms of life-threatening arrhythmia||Permanently discontinue Tagrisso.|
|Symptomatic congestive heart failure||Permanently discontinue Tagrisso.|
|Cutaneous||Stevens-Johnson syndrome (SJS), Erythema Multiforme Major (EMM)||Withhold Tagrisso if suspected and permanently discontinue if confirmed.|
|Other||Adverse reaction of Grade 3 or greater severity||Withhold Tagrisso for up to 3 weeks.|
|If improvement to Grade 0-2 within 3 weeks||Resume at 80 mg or 40 mg daily.|
|If no improvement within 3 weeks||Permanently discontinue Tagrisso.|
|*Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0).|
†QTc = QT interval corrected for heart rate
‡ECGs = Electrocardiogram
Strong CYP3A4 Inducers
What drugs interact with Tagrisso?
Effect Of Other Drugs On Osimertinib
Strong CYP3A Inducers
- Co-administering Tagrisso with a strong CYP3A4 inducer decreased the exposure of osimertinib compared to administering Tagrisso alone. Decreased osimertinib exposure may lead to reduced efficacy.
- Avoid co-administering Tagrisso with strong CYP3A inducers. Increase the Tagrisso dosage when co-administering with a strong CYP3A4 inducer if concurrent use is unavoidable. No dose adjustments are required when Tagrisso is used with moderate and/or weak CYP3A inducers.
Effect Of Osimertinib On Other Drugs
- Co-administering Tagrisso with a breast cancer-resistant protein (BCRP) or P-glycoprotein (P-gp) substrate increased the exposure of the substrate compared to administering it alone.
- Increased BCRP or P-gp substrate exposure may increase the risk of exposure-related toxicity.
- Monitor for adverse reactions of the BCRP or P-gp substrate, unless otherwise instructed in its approved labeling, when co-administered with Tagrisso.
Drugs That Prolong The QTc Interval
- The effect of co-administering medicinal products known to prolong the QTc interval with Tagrisso is unknown.
- When feasible, avoid concomitant administration of drugs known to prolong the QTc interval with known risk of Torsades de pointes.
- If not feasible to avoid concomitant administration of such drugs, conduct periodic ECG monitoring.
Is Tagrisso safe to use while pregnant or breastfeeding?
Latest Cancer News
Daily Health News
Tagrisso (osimertinib) is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s). Tagrisso may cause serious side effects, including lung problems, heart problems, severe blistering or peeling of skin, and target lesions.
Multimedia: Slideshows, Images & Quizzes
Lung Cancer: Early Signs, Symptoms, Stages
Learn about lung cancer early warning signs, symptoms and treatments. What causes stage IV lung cancer? Get more information on...
Lung Cancer Risks: Myths and Facts
Learn about lung cancer myths and facts. Explore how cigar smoke, menthol, and pollution can increase your risk of lung cancer...
Lung Cancer Quiz: Signs and Symptoms
Lung cancer is the number one cause of cancer deaths in both men and women in the U.S. and worldwide. Get the facts about lung...
Picture of Lung Cancer
Cancer of the lung, like all cancers, results from an abnormality in the body's basic unit of life, the cell. See a picture of...
Related Disease Conditions
Lung cancer kills more men and women than any other form of cancer. Eight out of 10 lung cancers are due to tobacco smoke. Lung cancers are classified as either small-cell or non-small-cell lung cancers.
Small Cell Lung Cancer vs. Non-Small Cell Lung Cancer
Non-small cell lung cancers (NSCLC) consist of large cell carcinomas, adenocarcinomas, and squamous cell carcinomas. Small cell lung cancer (SCLC) usually starts in the bronchi and typically appears in those who smoke. SCLC and NSCLC are staged in different manners, and SCLC tends to metastasize more quickly than NSCLC. Signs and symptoms of NSCLC and SCLC include shortness of breath, coughing up blood, recurring lung infections, and chest pain. Treatment may involve radiation therapy, chemotherapy, and surgery.
What Are the Four Types of Lung Cancer?
The four types of lung cancer are classified by what kind of cells the cancer affects and what the tumor cells look like under a microscope. Lung cancers can be small-cell or non-small cell, further classified as squamous cell carcinoma or adenocarcinoma.
Six Early Signs of Lung Cancer
Lung cancer is the third most common cancer in the United States. It may not show its signs and symptoms in its early stages. Signs and symptoms typically appear in the advanced stage of the disease.
Can Pancoast Lung Cancer Be Cured?
Pancoast tumors are a rare type of lung cancer that forms at the extreme top of either of the lungs. Due to their location at the top of the lung, there’s a high chance that cancer might attack the adjacent tissue and produce typical symptoms.
What Is the Survival Rate of Non-Small Cell Lung Cancer?
There are two main types of lung cancers, namely, small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC accounts for 85% of all lung cancer cases in the United States. It must be noted that medical science is progressing with leaps and bounds, and treatment for lung cancer must be initiated and maintained despite the stage of diagnosis.
Treatment & Diagnosis
- Lung Cancer FAQs
- Sensitive to Smoke, Lung Cancer Gene
- Lung Cancer and Chemotherapy
- Lung Cancer Signs and Symptoms
- 5 Causes of Lung Cancer in Non-Smokers
- Dana Reeve Dies of Lung Cancer by Dr. Stoppler
- What Is the Survival Rate for Lung Cancer Nodules?
- Why Does Lung Cancer Spread So Fast?
- Can You Get Lung Cancer After Quitting Smoking?
- Stage IV Lung Cancer With ALK (Anaplastic Lymphoma Kinase) Rearrangement
- Lung Cancer - Health Beat Audio Segment
Prevention & Wellness
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.